[Evaluation of carbenoxolone in long term treatment of recurrent duodenal ulcer (author's transl)].
A double-blind randomized trial was performed in order to evaluate the efficacy of carbenoxolone (Biogastron duodenal) in reducing recurrences of duodenal ulcer. Eighty-one patients with endoscopically proven recurrent duodenal ulcer (at least a painful ulcer episodes within the past two years) were randomized. Fourty-six were assigned to carbenoxolon (50 mg Biogastron duodenal three times daily) and 35 to placebo. Every month the patients were seen in the out-patient department and asked for symptoms, especially typical pain, and - if indicated - examined by gastrofiberscopy. After about two years, 72 percent of the patients treated with carbenoxolone and 66 percent ot the placebo group remained without recurrence. The difference is not significant.
D000328:Adult; D000368:Aged; D002229:Carbenoxolone / Q000627:therapeutic use*; D004311:Double-Blind Method; D004381:Duodenal Ulcer / Q000188:drug therapy*; D005260:Female; D006034:Glycyrrhetinic Acid / Q000031:analogs & derivatives*; D006801:Humans; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D012008:Recurrence
D002229:Carbenoxolone; D006034:Glycyrrhetinic Acid
Versuche zur Langzeittherapie mit Carbenoxolon beim Ulcus duodeni.